Nov. 9, 2020—Yi Ren, assistant professor of biochemistry, has contributed to research on the function and impact of the SARS-CoV-2 protein on immune signaling protein in host cells. This understanding may lead to the development of immune-enhancing therapeutics.
Oct. 15, 2020—It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.
COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
Oct. 7, 2020—Vanderbilt’s Data Science Institute, Department of Economics and Public Policy Studies Program, in partnership with the nonpartisan Sycamore Institute, are co-hosting a virtual discussion with celebrated economist and Harvard professor Raj Chetty on the economic impact of COVID-19. Chancellor Daniel Diermeier will deliver opening remarks.
Vanderbilt researchers develop publicly available COVID-19 animal susceptibility prediction tool; suggests increased risk to horses
Oct. 6, 2020—All-remote collaboration results in free animal susceptibility tool to help prioritize research and closer examination of at-risk species.
Sep. 22, 2020—Vanderbilt researchers have been awarded a National Science Foundation Convergence Accelerator 2020 Cohort Phase 1 grant to create a standardized platform that will streamline the development, testing and dissemination of technology that can improve human health. The nine-month project, “Scalable, Traceable AI for Imaging Translation: Innovation to Implementation for Accelerated Impact (STRAIT I3),” looks specifically...
Sep. 20, 2020—Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19.
Sep. 11, 2020—Derek Griffith, professor of medicine, health and society and founding director of the Center for Research on Men’s Health, takes an intersectional approach to researching the impacts of COVID-19, advocating for a more nuanced understanding of identity’s role in determining risk to enhance policy reforms toward greater health equity.